<DOC>
	<DOCNO>NCT03029832</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , placebo-controlled , double-blind study evaluate safety efficacy MOXR0916 combination atezolizumab versus placebo atezolizumab participant locally advance metastatic urothelial carcinoma ( UC ) receive prior systemic therapy locally advanced/metastatic set ineligible receive cisplatin-based therapy .</brief_summary>
	<brief_title>A Study MOXR0916 Combination With Atezolizumab Versus Atezolizumab Alone Participants With Untreated Locally Advanced Metastatic Urothelial Carcinoma Who Are Ineligible Cisplatin-Based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age &gt; = 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 Life expectancy &gt; = 12 week Histologically cytologically confirm locally advanced metastatic urothelial carcinoma ( UC ) Availability representative formalinfixed paraffinembedded tumor specimen No prior systemic therapy inoperable locally advanced metastatic UC Ineligible cisplatinbased chemotherapy define one follow criterion : Impaired renal function ( glomerular filtration rate [ GFR ] &gt; 30 &lt; 60 milliliter/minute [ mL/min ] ) ; National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) version ( v ) 4.0 Grade &gt; = 2 audiometric hearing loss ( 25 Decibel two contiguous frequency severe ) ; NCI CTCAE v 4.0 Grade &gt; = 2 peripheral neuropathy ; ECOG Performance Status 2 Measurable disease accord Response Evaluation Criteria Solid Tumors v1.1 Adequate hematologic endorgan function Significant cardiovascular disease Known clinically significant liver disease Any approve anticancer therapy , include chemotherapy hormonal therapy , within 3 week prior initiation study treatment Prior treatment CD137 OX40 agonist , anti−cytotoxic Tlymphocyteassociated protein ( CTLA4 ) , anti−programmed death1 ( PD1 ) , anti program deathligand 1 ( PDL1 ) , antiCD27 , anti glucocorticoidinduced tumor necrosis factor receptor ( GITR ) therapeutic antibody pathwaytargeting agent Untreated central nervous system ( CNS ) metastases active ( progress require corticosteroid symptomatic control ) CNS metastases Any history leptomeningeal disease Malignancies UC within 5 year prior Cycle 1 , Day 1 History autoimmune disease History idiopathic pulmonary fibrosis , pneumonitis , organize pneumonia , evidence active pneumonitis screen chest compute tomography scan Active hepatitis B C virus infection Positive HIV test screen Active tuberculosis Prior allogeneic stem cell solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>